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11 Abstract
12 Background: Active cancer immunotherapies are beginning to yield clinical benefit, especially those using peptide-
13 pulsed dendritic cells (DCs). Different adjuvants, including Toll-like receptor (TLR) agonists, commonly co-
14 administered to cancer patients as part of a DC-based vaccine, are being widely tested in the clinical setting.
15 However, endogenous DCs in tumor-bearing individuals are often dysfunctional, suggesting that ex vivo educated
16 DCs might be superior inducers of anti-tumor immune responses. We have previously shown that prothymosin
17 alpha (proTα) and its immunoreactive decapeptide proTα(100–109) induce the maturation of human DCs in vitro.
18 The aim of this study was to investigate whether proTα- or proTα(100–109)-matured DCs are functionally
19 competent and to provide preliminary evidence for the mode of action of these agents.
20 Results: Monocyte-derived DCs matured in vitro with proTα or proTα(100–109) express co-stimulatory molecules
21 and secrete pro-inflammatory cytokines. ProTα- and proTα(100–109)-matured DCs pulsed with HER-2/neu peptides
22 induce TH1-type immune responses, prime autologous naïve CD8-positive (+) T cells to lyse targets expressing the
23 HER-2/neu epitopes and to express a polyfunctional profile, and stimulate CD4+ T cell proliferation in an HER-2/neu
24 peptide-dependent manner. DC maturation induced by proTα and proTα(100–109) is likely mediated via TLR-4, as
25 shown by assessing TLR-4 surface expression and the levels of the intracellular adaptor molecules TIRAP, MyD88
26 and TRIF.
27 Conclusions: Our results suggest that proTα and proTα(100–109) induce both the maturation and the T cell
28 stimulatory capacity of DCs. Although further studies are needed, evidence for a possible proTα and proTα(100–109)
29 interaction with TLR-4 is provided. The initial hypothesis that proTα and the proTα-derived immunoactive decapeptide
30 act as “alarmins”, provides a rationale for their eventual use as adjuvants in DC-based anti-cancer immunotherapy.
31 Keywords: Prothymosin alpha, Immunoreactive peptide, Dendritic cells, TH1 immune responses, TLR-4, Adjuvant,
32
HER-2/neu peptides
33 Background
34 Anti-cancer vaccines are designed to break tolerance to
35 self and stimulate strong and durable anti-tumor im-
36 munity. Administering defined tumor-derived epitopes
37 to cancer patients for the activation of helper and cyto-
38 toxic T cells has been shown to enhance anti-cancer im-
39 mune responses in vivo and in some cases to lead to
40objective clinical responses [1-3]. To optimize the
41efficacy of peptide-based anti-cancer vaccines, combina-
42torial approaches stimulating both innate and adaptive
43immunity are now being clinically evaluated [4,5].
44Mature dendritic cells (DCs) are key players for eliciting
45such responses, as they present antigens to T cells and
46provide the necessary co-stimulatory signals and cyto-
47kines favoring the efficient activation of tumor-reactive
48immune cells [6,7]. DC maturation can be induced
49in vivo upon admixing and co-administering immuno-
50genic peptides with adjuvants, but to date this strategy
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51 has been proven successful only when vaccinating against
52 common pathogens [8]. In cancer patients, the presence
53 of tumor-associated suppressive factors impairs endogen-
54 ous DC functions [9], a condition that can be bypassed
55 only by the adoptive transfer of ex vivo matured immuno-
56 competent DCs [10,11].
57 Adjuvants comprise, among others, Toll-like receptor
58 (TLR) agonists, the majority of which reportedly promotes
59 DC maturation [12]. A subcategory thereof are molecules
60 with so-called pathogen-associated molecular patterns
61 (PAMPs), such as CpG oligodeoxynucleotides that signal
62 through TLR-9 [13], poly-I:C ligating TLR-3 [14],
63 imiquimod, a TLR-7 agonist [15] and monophosphoryl
64 lipid A, a TLR-4 agonist [16]. A second group consists of
65 molecules possessing damage-associated molecular pat-
66 terns (DAMPs) or “alarmins”. High mobility group box 1
67 (HMGB1) protein and heat shock protein (HSP) 90 are
68 notable examples of DAMPs. Both proteins are strictly
69 intracellular under normal physiological conditions, but
70 when excreted eg. from damaged cells, signal through
71 TLR-4, sensitize DCs and promote adaptive immune re-
72 sponses [17]. This functional dualism, in and out of the
73 cell, also characterizes prothymosin alpha (proTα).
74 In normal living cells, proTα is localized in the nucleus
75 where it controls the cell cycle and promotes cell prolif-
76 eration. Released from dead cells, extracellular proTα ac-
77 quires multi-functional immunomodulatory properties
78 [18]. We and others have previously shown that proTα
79 upregulates the expression of IRAK-4 in human mono-
80 cytes [19], ligates TLR-4 on murine macrophages and
81 signals through MyD88-dependent and independent path-
82 ways [20]. Similar to its immunoreactive decapeptide
83 proTα(100–109) [21], it upregulates the expression of
84 HLA-DR [22], CD80, CD83 and CD86 and promotes mat-
85 uration of human DCs in vitro [23].
86 Here, we show that DCs matured ex vivo in the presence
87 of proTα or proTα(100–109) are not only phenotypically
88 but also functionally competent, secrete pro-inflammatory
89 cytokines and induce TH1-type immune responses in the
90 presence of tumor-associated immunogenic epitopes of
91 the oncoprotein HER-2/neu. DCs matured with proTα or
92 proTα(100–109) prime naïve CD8-positive (+) T cells to
93 exert HER-2/neu peptide-specific cytotoxicity and CD4+
94 T cells to proliferate in a peptide-dependent manner.
95 Finally, we provide preliminary evidence suggesting that
96 both proTα and its decapeptide proTα(100–109) likely
97 signal viaTLR-4 in human DCs.
98 Results
99 Phenotype of and cytokine production by proTα- or
100 proTα(100–109)-matured DCs
101 We have previously shown that proTα and proTα(100–109)
102 efficiently mature human DCs in vitro, as indicated by
103 the induction of surface expression of established DC-
104markers to levels comparable to those induced by
105lipopolysacharide (LPS) [23] or tumor necrosis factor
106(TNF)-α (this report). As shown in Figure F11, LPS-
107matured DCs significantly upregulated the expression
108of HLA-DR, CD11b, CD80, CD83, CD86 and CD40, to
109levels comparable to TNF-α-matured DCs (p < 0.001
110compared to iDCs for all values). Similarly, both agents
111caused a reduction of CD14 expression. In agreement
112with our previous study [23], iDCs matured with either
113proTα or its decapeptide presented a similar phenotype
114to LPS- or TNF-α-matured DCs, upregulating the ex-
115pression of all co-stimulatory molecules (p < 0.05-0.001,
116compared to iDCs; Figure 1) and downregulating CD14
117(p < 0.01, compared to iDCs).
118In conjunction with their phenotype, functionally com-
119petent mature DCs secrete pro- and anti-inflammatory
120cytokines [6]. Therefore, we assessed the production of
121TNF-α, interleukin (IL)-12 and IL-10 from iDCs and
122mature DCs and determined the IL-12:IL-10 ratio. We
123present these data because high TNF-α levels, as well as
124a balance between IL-12:IL-10 in favor of IL-12 have
125been proposed to promote TH1-polarization [24]. As
126shown in Figure F22, iDCs produced low amounts of all
127three cytokines, whereas mature DC supernatants col-
128lected 48 h after addition of LPS or TNF-α were rich in
129TNF-α and IL-12. Compared to iDCs, higher TNF-α
130and IL-12 levels were also found in supernatants of cul-
131tures of DCs matured with proTα and proTα(100–109).
132Although the absolute concentrations of cytokines varied
133among the differentially matured DCs, their overall
134cytokine-production patterns were comparable. Most
135importantly, the mean IL-12:IL-10 ratios were similar
136(6.61, 6.45, 7.89 and 5.18, for LPS-, TNF-α-, proTα- and
137proTα(100–109)-matured DCs, respectively). These data
138suggest that the peptides bias immunoreactivity towards
139a pro-inflammatory TH1-type of response.
140Finally, in the presence of a blocking antibody against
141TLR-4 (a-TLR-4; Figure 2), lower amounts of cytokines
142were secreted by LPS-, proTα- and proTα(100–109)-
143matured DCs, but not TNF-α-matured DCs. Notably,
144a-TLR-4 reduced the levels of LPS- and proTα-induced
145IL-12 production by 55 and 47%, respectively (p < 0.05),
146implying that IL-12 production by LPS- and proTα-
147matured DCs is at least partially, TLR-4-dependent [25].
148ProTα and proTα(100–109) lead to TH1-polarized tumor
149peptide-reactive immune response
150As optimally matured DCs prime antigen-specific CD4+
151and CD8+ T cell activation and proliferation of naive
152T cells [7], we next assessed whether proTα- and
153proTα(100–109)-matured DCs are functionally compe-
154tent, i.e., induce in vitro the selective expansion of tumor
155antigen-specific T cells.
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Figure 1 ProTα or proTα(100–109) induce DC maturation. Monocytes were differentiated to immature DCs (iDCs) upon 5-day incubation with
GM-CSF and IL-4, followed by 48 h exposure to LPS, TNF-α, proTα or proTα(100–109). Expression of surface HLA-DR, CD11b, CD80, CD83, CD86, CD40
and CD14 on iDCs and mature DCs are shown as mean fluorescence intensity (MFI) ± SD from 5 donors. * p < 0.05; ** p < 0.01; *** p < 0.001, compared
to iDCs.
Figure 2 ProTα- or proTα(100–109)-matured DCs secrete pro-inflammatory cytokines. Culture supernatants from iDCs and DCs matured
with LPS, TNF-α, proTα or proTα(100–109) for 48 h were assessed for their TNF-α, IL-12 and IL-10 content. iDCs were treated (+) or not (−) with an
anti-TLR-4 mAb (a-TLR-4) for 1 h prior to their maturation. Data are given as mean values ± SDs from 3 donors. * p < 0.05.
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156 Monocyte-derived DCs matured for 48 h with proTα,
157 proTα(100–109) or TNF-α (used as a conventional DC
158 maturation agent) were pulsed with the HLA-A2 and
159 HLA-DR4-restricted HER-2/neu(369–377) [HER-2(9369)]
160 and HER-2/neu(776–790) [HER-2(15776)] epitopes, and
161 used to prime autologous naïve T cells isolated from the
162 peripheral blood of HLA-A2+/DR4+ healthy donors.
163 T cells were restimulated twice, at weekly intervals, with
164 similarly matured autologous DCs. Twelve hours after the
165 third stimulation their production of TNF-α, interferon
166 (IFN)-γ, IL-2, IL-4, IL-10 and IL-17 was analysed. FigureF3 3
167 shows the percentages of IFN-γ+, IL-2+, IL-4+ and IL-10+
168 CD4+ T cells from one representative donor of 5 tested
169 with similar results (Additional file 1: Table S1A). In the
170 presence of unpulsed TNF-α-matured DCs, only a low
171 percentage of CD4+ T cells produced IFN-γ (0.02%),
172 which was significantly increased (23.30%) in the presence
173 of the HER-2/neu peptides. An analogous increase in the
174 percentage of IFN-γ-producing cells was also recorded in
175 CD4+ T cells stimulated with proTα- or proTα(100–109)-
176 matured DCs in the presence of the same peptides
177 (21.78% and 22.93%, respectively, compared to 0.01% and
178 0.02% in the absence of HER-2/neu peptides; Figure 3).
179 The percentages of IL-2-producing CD4+ T cells in all
180 groups were also significantly enhanced upon stimulation
181 with HER-2/neu peptide-pulsed DCs (35.02% for TNF-α-,
182 31.51% for proTα- and 37.18% for proTα(100–109)-
183matured DCs, compared to 0.08%, 0.09% and 0.71% of the
184respective unpulsed groups; Figure 3). A similar en-
185hancement was also seen for TNF-α-producing CD4+
186T cells (Additional file 1: Table S1A). In contrast,
187production of IL-4 and IL-10 was only marginally in-
188creased when CD4+ T cells were stimulated with HER-
1892/neu peptide-pulsed DCs, regardless of the factor used
190for DC maturation (Figure 3). Specifically, the percent-
191age of CD4+ T cells producing IL-4 was increased from
1920.01% (without peptides) to 1.17% among T cells stimu-
193lated with peptide-pulsed TNF-α-matured DCs, from
1940.01% to 0.61% in the proΤα- and from 0.02% to 0.82%
195in the proTα(100–109)-matured DC groups. A minor
196enhancement was also recorded for IL-10 production;
197IL-10+ cells increased from 0.03% to 0.11% in the TNF-α-,
198from 0.01% to 0.02% in the proΤα- and from 0.01% to
1990.02% in the proTα(100–109)-matured DC cultures with-
200out and with HER-2/neu peptides, respectively. IL-17 pro-
201duction exhibited a similar pattern of marginal increase in
202CD4+ T cells stimulated in the presence of all matured
203antigen-pulsed DCs (Additional file 1: Table S1A). These
204data suggest that proTα- and proTα(100–109)-matured
205DCs are immunocompetent and in the presence of spe-
206cific tumor antigenic epitopes, favor the in vitro produc-
207tion of pro-inflammatory (IFN-γ, IL-2, TNF-α), rather
208than anti-inflammatory cytokines (IL-4, IL-10) and IL-17
209by CD4+ T cells, inducing TH1-type immune responses.
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Figure 3 T cells stimulated with proTα- or proTα(100–109)-matured HER-2/neu-peptide-pulsed autologous DCs produce TH1-type
cytokines. Monocytes from HLA-A2+/DR4+ donors were differentiated to iDCs, matured for 48 h with TNF-α, proTα or proTα(100–109), pulsed
with HER-2(9369) and HER-2(15776) epitopes and used to stimulate autologous T cells. Recovered CD4+ T cells were analyzed for intracellular
production of IFN-γ, IL-2, IL-4 and ΙL-10, in the absence (−) or presence (+) of the HER-2/neu peptides. First row, DCs matured with TNF-α; middle
row, DCs matured with proTα; bottom row, DCs matured with proTα (100–109). Numbers indicate percentage of positive cells for each cytokine
on gated CD4+ T cells. Shown data are from one representative donor of 5 tested.
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210 ProTα- and proTα(100–109)-matured DCs stimulate tumor
211 peptide-specific CD8+ T cell responses
212 Cell-mediated immunity requires initial collaboration
213 between TH1 CD4+ and CD8+ T cells [26]. Thus, we
214 next investigated whether proTα- and proTα(100–109)-
215matured DCs can elicit tumor peptide-specific cytotoxic
216T cell immune responses.
217CD8+ T cells recovered from the same stimulation
218cultures as aforementioned were assessed for the intra-
219cellular production of TNF-α. As shown in Figure F44A,
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Figure 4 T cells stimulated with proTα- or proTα(100–109)-matured DCs are cytotoxic in the presence of HER-2(9369). (A) Intracellular
production of TNF-α (left) and surface expression of CD107a (right) in CD8+ T cells stimulated with DCs matured for 48 h with TNF-α (first row),
proTα (middle row) or proTα(100–109) (bottom row), in the absence (−) or presence (+) of the HER-2/neu peptides. Numbers indicate
percentages of positive cells on gated CD8+ T cells. Shown are data from one representative experiment of 5 performed. (B) T cells stimulated
with TNF-α-, proTα- or proTα(100–109)-matured DCs, were used as effectors (E) against unloaded, HER-2(9369)- and tyr(9369)-loaded T2 targets (T).
Where indicated, mAb to MHC class I molecules was added throughout the culture period at a final concentration of 5 μg/mL. In all assays the E:
T ratio was 10:1. Data represent mean % cytotoxicity ± SD from 2–5 donors.
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220 they also exhibited a similar pattern of enhanced cyto-
221 kine production in the presence of HER-2/neu peptides
222 as did CD4+ T cells. The percentage of TNF-α + cells
223 was increased from 0.35% (unpulsed) to 47.52% (pulsed)
224 when T cells were stimulated with TNF-α-matured DCs,
225 and from 0.12% to 45.38% for proTα- and from 0.13% to
226 42.88% for proTα(100–109)-matured DCs (Figure 4A).
227 In addition and in accordance with the results recorded
228 for CD4+ T cells, IL-2- and IFN-γ-producing CD8+ T cells
229 were also increased in the presence of peptide-pulsed
230 DCs in the cultures, whereas differences in the percent-
231 ages of IL-10-producing CD8+ T cells were only mar-
232 ginal (Additional file 1: Table S1A).
233 The same cells were assessed for the expression of
234 CD107a, as a surrogate marker for cytotoxicity [27]. In
235 the absence of HER-2(9369), a low percentage of CD8+
236 T cells stimulated with TNF-α-matured DCs expressed
237 CD107a (3.70%; Figure 4A), which increased when cells
238 were stimulated with HER-2(9369)-pulsed DCs (54.75%).
239 Similar CD107a upregulation was observed in CD8+
240 T cells stimulated with proTα- and proTα(100–109)-
241 matured HER-2(9369)-pulsed DCs (36.86% and 41.99%,
242 respectively, compared to 2.80% and 2.17% of the
243 unpulsed groups; Figure 4A). Since TNF-α mediates target
244 cell damage and CD107a-expressing CD8+ T cells are
245 cytotoxic [27], our results suggest that proTα- and
246 proTα(100–109)-matured DCs efficiently activate CD8+
247 cytotoxic T cells, which were able to kill targets presenting
248 the immunogenic epitope versus which they were primed.
249 Cytotoxic activity was verified by using 51Cr-labeled
250 HLA-A2+ T2 cells loaded with HER-2(9369) or an irrele-
251 vant epitope, tyrosinase(369–377) [tyr(9369)]. CD8+ T cells
252 thrice stimulated with peptide-pulsed TNF-α-, proTα- or
253 proTα(100–109)-matured DCs were coincubated with
254these peptide-loaded T2 targets. The results showed that
255CD8+ T cell mean cytotoxicity against non-peptide loaded
256T2 targets did not exceed 30% in any group (26.9% for
257TNF-α, 23.7% for proTα- and 21.4% for proTα(100–109)-
258matured DCs; Figure 4B), whereas HER-2(9369)-loaded T2
259targets were lysed twice as efficiently by CD8+ T cells re-
260covered from all stimulation cultures (49.9% for TNF-α-,
26146.6% for proTα- and 40.4% for proTα(100–109)-matured
262DCs; Figure 4B). Cytotoxicity against T2 targets loaded
263with tyr(9369) was low and in no instance exceeded 30%.
264These cytotoxic responses were significantly decreased by
265monoclonal antibody (mAb) to MHC class I molecules,
266suggesting that the CD8+ T cells generated by our stimu-
267lation protocol are MHC class I-restricted and HER-2
268(9369)-specific (Figure 4B).
269Polyfunctionality of HER-2(9369)–specific CD8+ T cells
270Based on previous studies associating T cell polyfunctionality
271with high IFN-γ production and the quality of the elic-
272ited responses [28,29], we carried out a functional ana-
273lysis of the HER-2(9369)-specific CD8+ T cells
274generated in these experiments. Using FlowJo software,
275we analyzed their ability to produce effector cytokines
276(IFN-γ, TNF-α and IL-2) and to degranulate (expression
277of CD107a). Quantifying the fraction of the responsive
278CD8+ T cells producing any one (1+), any two (2+), any
279three (3+) or all four (4+) mediators, we observed that ap-
280proximately a mean ~16% of the responsive CD8+ T cells
281were 2+ cells, regardless of the agent used to mature the
282DCs that stimulated them (16.26% for TNF-α; 16.92%
283for proTα; 15.95% for proTα(100–109); Figure F55). In all
284experimental groups, 3+ cells were also detected in in-
285creased percentages (8.13% for TNF-α; 7.03% for proTα;
2864.34% for proTα(100–109)). In contrast, very few 4+ cells
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Figure 5 HER-2(9369)-specific T cells, stimulated with proTα- or proTα(100–109)-matured DCs, are polyfunctional. The proportion of cells
producing IFN-γ, TNF-α, IL-2 or CD107a was determined in total responsive CD8+ T cells recovered from cultures stimulated with DCs matured
with TNF-α, proTα or proTα(100–109). Mean ± SE of data obtained from 3 different donors are shown.
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287 were detected under any conditions. Taken together, these
288 data suggest that proTα- or proTα(100–109)-matured
289 DCs were able to induce polyfunctional (2+, 3+) CD8+
290 peptide-specific T cell responses at least as well as
291 TNF-α-matured DCs.
292 T cells stimulated with proTα- or proTα(100–109)-matured
293 DCs proliferate in response to the HER-2(15776) epitope
294 T cell proliferation was assessed by the incorporation of
295
3H-thymidine. HER-2(15776)-sensitized T cells coincubated
296 with HER-2(15776)-, tyrosinase(448–462) [tyr(15448)]-pulsed
297 or unpulsed DCs, specifically proliferated in response
298 only to the HER-2/neu epitope (TableT1 1). ProTα- and
299 proTα(100–109)-matured DCs showed relatively high
300 mean stimulation indices (S.Is) (2.64 and 2.26, respect-
301 ively), comparable to those recorded for TNF-α-matured
302 DCs (3.09). Addition of mAb to MHC class II molecules
303 reduced mean S.Is in all groups (0.87 for TNF-α; 0.93 for
304 proTα; 0.98 for proTα(100–109)). These results suggest
305 that following our in vitro culture protocol, peptide-
306 reactive T cells are generated, which proliferate only in a
307 HER-2(15776)-dependent MHC class II-restricted manner.
308 ProTα and proTα(100–109) induce the maturation of DCs
309 via triggering TLR-4
310 We have previously reported that stimulation of human
311 monocytes with proTα upregulated IRAK-4, a protein
312 kinase involved in TLR downstream signaling [19],
313 whereas Mosoian et al. [20] showed that proTα ligates
314 TLR-4 and signals through both TRIF- and MyD88-
315 dependent pathways. To determine whether TLR-4 is
316 triggered by our peptides, we studied the kinetics of TLR-
317 4 surface expression on proTα and proTα(100–109)-
318 stimulated DCs. Immature DCs (iDCs) and DCs matured
319with LPS (a known TLR-4 ligand; [30]), proTα or
320proTα(100–109) for 15 min, 30 min, 1 h, 18 h and 36 h
321were analyzed by flow cytometry. The percentage of sur-
322face TLR-4 expression over time is presented in Figure F66.
323Maturation of DCs with LPS led to an early (15 and
32430 min) decrease of TLR-4 expression (by ~15%) due to
325internalization [31], and a subsequent increase from 1 to
32618 h [32]. At 36 h post-LPS addition, TLR-4 expression was
327lower and comparable to that of iDCs (0 h). ProTα and
328proTα(100–109), marginally downregulated TLR-4 expres-
329sion at 30 min and, similarly to LPS, transiently increased it
330from 1 to 18 h. As with LPS-matured DCs, basal levels of
331TLR-4 expression were detected at 36 h post-maturation.
332The similar kinetics of TLR-4 expression in LPS-, proTα-
333and proTα(100–109)-matured DCs is consistent with the
334notion that the two peptides interact with TLR-4.
335To extend these findings, we next investigated the
336intracellular expression levels of three adaptor molecules
337that participate in signaling pathways downstream of
338TLR-4, namely TRIF, an adaptor molecule common to
339TLR-3 and -4 signaling; TIRAP, a signaling adaptor com-
340mon to TLR-2, and -4; and MyD88, a molecule
341upregulated upon ligation of all TLRs except TLR-3 [33].
342We specifically selected these three adaptors because this
343constellation is unique to TLR-4 activation. Total cell ex-
344tracts from iDCs and DCs matured with LPS, proTα or
345proTα(100–109) for 1 h and 18 h were immunoblotted
346(Figure F77A). Upon densitometric quantification of each
347protein band detected, expression relative to GAPDH was
348calculated. As shown in Figure 7B, addition of LPS led to
349a significant ~2-3 fold increase of the expression of all
350three adaptors within 1 h (3.05 for TRIF, 2.88 for TIRAP
351and 1.81 for MyD88) relative to iDCs (1.38 for TRIF, 1.00
352for TIRAP and 0.74 for MyD88). At 18 h post-addition of
t1:1 Table 1 T cells stimulated with proTα- or proTα(100–109)-matured DCs proliferate in the presence of HER-2(15776)-
t1:2 pulsed DCs
t1:3 DCs matured with DCs pulsed with Mean counts per minute
(cpm) ± SD*
Stimulation index
(S.I.) ± SD*
t1:4 TNF-α - 13693 ± 1413 1
t1:5 HER-2(15776) 42314 ± 7139 3.09 ± 0.52
t1:6 tyr(15448) 16433 ± 1840 1.20 ± 0.13
t1:7 HER-2(15776) + anti-MHC class II 11914 ± 2033 0.87 ± 0.15
t1:8 ProTα - 13145 ± 1742 1
t1:9 HER-2(15776) 34702 ± 5143 2.64 ± 0.39
t1:10 tyr(15448) 17220 ± 2974 1.31 ± 0.23
t1:11 HER-2(15776) + anti-MHC class II 12225 ± 2603 0.93 ± 0.20
t1:12 ProTα(100–109) - 14577 ± 1041 1
t1:13 HER-2(15776) 32944 ± 6567 2.26 ± 0.45
t1:14 tyr(15448) 15306 ± 3608 1.05 ± 0.25
t1:15 HER-2(15776) + anti-MHC class II 14285 ± 2989 0.98 ± 0.20
t1:16 * Mean cpm, S.I. ± SD from 2–5 donors.
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353 LPS, expression of all adaptors was decreased and again
354 comparable to iDCs (1.35 for TRIF, 1.16 for TIRAP and
355 1.20 for MyD88). A similar trend of increased expression
356 was also observed 1 h after addition of proTα (2.537 for
357 TRIF, 2.28 for TIRAP and 1.577 for MyD88) or
358 proTα(100–109) (1.62 for TRIF, 1.423 for TIRAP, 1.06 for
359 MyD88), although in the latter case, the detected protein
360 levels were lower. As with LPS, 18 h after proTα or
361 proTα(100–109) DC-stimulation, the expression of TRIF,
362 TIRAP and MyD88 was reduced and was similar to iDCs.
363 These data, in conjunction with the cytokine profile
364 shown in Figure 2, suggest that LPS, proTα, and possibly
365 also proTα(100–109), activate DCs at least partly through
366 one common TLR-4-dependent intracellular signaling
367 pathway.
368 Discussion
369 We have previously shown that human monocyte-
370 derived iDCs activated in vitro with proTα or its immu-
371 noreactive decapeptide, proTα(100–109), acquire a
372 mature DC phenotype [23]. Here, we show that DC mat-
373 uration induced by proTα or proTα(100–109) promotes
374 the secretion of IL-12, rather than IL-10, from these
375 cells. Thus, both proTα- and proTα(100–109)-matured
376 DCs possess immunostimulatory properties appropriate
377for the efficient activation of T cells, through their en-
378hanced antigen-presenting capacity (HLA-DR; signal 1),
379the increased expression of co-stimulatory molecules
380(CD80/CD86; signal 2) and the secretion of inflamma-
381tory mediators (IL-12), recently proposed to act as signal
3823 for optimizing effector T cell functions [34,35].
383We assessed whether these ex vivo generated DCs can
384present tumor-associated immunogenic peptides to au-
385tologous T cells, along with the appropriate signals for
386their activation. We pulsed DCs with one MHC class I-
387and one class II-restricted immunodominant epitope
388from the oncoprotein HER-2/neu, HER-2(9369) and
389HER-2/neu(15776), respectively [36,37]. Our results show
390that proTα- or proTα(100–109)-matured HER-2/neu
391peptide-pulsed DCs favor the generation of TH1-type
392immune responses in vitro, by polarizing CD4+ T cells
393to produce pro-inflammatory cytokines. This cytokine
394milieu, characterized by high levels of IFN-γ and IL-2,
395results in the generation of strong CD8+ T cell
396responses [26,38], as we also observed. Indeed, CD8+
397effectors recovered from the same stimulation cultures
398exhibited a pro-inflammatory cytokine profile similar to
399the CD4+ T cells (Additional file 1: Tables S1A and B) and
400enhanced HER-2(9369)-specific MHC class I-restricted
401cytotoxicity. Of interest, a high percentage of the peptide-
Figure 6 Expression of TLR-4 on DCs matured with LPS, proTα or proΤα(100–109). iDCs differentiated from human monocytes (0 h) were
matured with LPS, proΤα and proΤα(100–109) for 15 min, 30 min, 1 h, 18 h and 36 h, and analyzed for TLR-4 surface expression. Data show mean
TLR-4 surface expression ± SD from 3 donors.
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402 specific CD8+ T cells generated in our stimulation cul-
403 tures were polyfunctional, a quality reportedly associated
404 with superior T cell performance [28,29,39]. These find-
405 ings, in conjunction with the observed enhancement of
406 HER-2(15776)-specific T cell proliferation, suggest that in
407 the presence of tumor antigenic peptides, proTα- and
408 proTα(100–109)-matured DCs efficiently promote the ex-
409 pansion of peptide-specific T cells.
410 Different DC-stimulating agents, including TLR li-
411 gands, have long been and still are being explored to
412 optimize the immunostimulatory properties of DCs
413 [10,11,40,41]. Although it was initially proposed that
414 TLRs recognized only PAMPs, accumulating evidence to
415 date suggests that TLRs also bind and respond to en-
416 dogenous ligands released during tissue injury and in-
417 flammation, termed DAMPs or “alarmins” [42]. Most
418prominent among the alarmins are HMGB1, members
419of the HSP family and granulysin [43], all of which ma-
420ture and activate DCs in vitro and bias immune re-
421sponses towards a TH1-type, when used as vaccine
422adjuvants in vivo [44-48]. We and others have previously
423shown that proTα promotes antigen-specific adaptive
424immune responses [20,49-52] and based on the data
425presented herein, we now identify proTα as an alarmin.
426Moreover, in line with data on immunoreactive peptide-
427fragments derived from either HMGB1 (Hp91; [53])
428or HSP70 (HSP70359-610; [46]), we show that the im-
429munologically active site of proTα, the decapeptide
430proTα(100–109) [23], also favors TH1-polarization and
431induces HER-2/neu peptide-specific immune responses.
432To suggest a possible molecular mechanism under-
433lying the effect of proTα and proTα(100–109), and
1h 18h
iDCs LPS (100-109) LPS (100-109)
1h 18h0h
TRIF
TIRAP
MyD88
GAPDH
35kDa  
35kDa  
76kDa  
37kDa  
A B
***
**
***
**
**
**
*
*
Figure 7 Increased TLR-4-associated adaptor molecule expression in human DCs matured with proTα or proTα(100–109). (A) Representative
immunoblots of TRIF, TIRAP and MyD88 expression in cell extracts of iDCs and DCs matured with LPS, proTα or proTα(100–109) for 1 h and 18 h.
GAPDH was used to verify equal loading. (B) Densitometry analysis of the adaptor proteins TRIF, TIRAP and MyD88, expressed as relative (%)
expression versus GAPDH. Mean values of 4 independent experiments ± SD are shown. * p < 0.05; ** p < 0.01; *** p < 0.001.
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434 considering recent data from ourselves and others [19,20],
435 we investigated whether TLR-4 expressed on human ma-
436 ture DCs is triggered by proTα or proTα(100–109). Our
437 results show that proTα- or proTα(100–109)-induced DC
438 maturation was associated with modulation of TLR-4
439 surface expression. Moreover, the expression of three
440 TLR-4-associated intracellular adaptors, TRIF, TIRAP and
441 MyD88, was promptly (at 1 h post-stimulation) increased
442 in proTα- or proTα(100–109)-matured DCs, providing in-
443 direct evidence that the adjuvant activity of proTα and
444 proTα(100–109) most likely involves TLR-4. Our data are
445 in agreement with those of Mosoian et al. [20], showing
446 that in murine macrophages proTα signals through the
447 MyD88- and the TRIF-dependent pathways inducing
448 TNF-α and type I IFN production, respectively. TLR
449 ligation is a common mechanism of action, shared by dif-
450 ferent DAMPs. TLR-2 and -4 are involved in HMGB1 sig-
451 naling in vitro [54-56], and several HSPs, including
452 HSP22, HSP60, HSP70 and HSP90 also act as TLR-4 ago-
453 nists [17,57-59]. Our results add to these observations,
454 suggesting that both proTα and its shorter immunoactive
455 decapeptide likely signal through TLR-4. The ambiguities
456 raised as to whether proTα and proTα(100–109) share a
457 common mechanism of action on DCs with LPS, could be
458 attributed to: (1) inadequate internalization of TLR-4 by
459 monocyte-derived human DCs, which reportedly are
460 CD14low (Figure 1, Additional file 2: Figure S1; [60,61]).
461 Indeed, stimulation of CD14high human monocytes and
462 monocyte-derived human macrophages (Additional file 3:
463 Figure S2) with proTα or proTα(100–109), induced the
464 rapid CD14-dependent endocytosis of TLR-4, with kin-
465 etics similar to the response to LPS (Additional file 2:
466 Figure S1); (2) differential requirements for TLR-4-medi-
467 ated signaling depending on the cell population (eg.
468 monocytes, macrophages versus DCs; [62]) and/or cell ori-
469 gin (eg. mouse versus human; [63]); and (3) the involve-
470 ment of other TLRs (eg. TLR-2) and/or PRRs in proTα-
471 and proTα(100–109)-induced DC signaling. In support of
472 the latter, a similar phenomenon has been described for
473 HMGB1; the intact protein signals through TLR-2 and -4
474 [53], and its immunostimulatory peptide Hp91 acts via
475 TLR-3 or even other receptors [45].
476 Conclusion
477 Taken altogether, we show herein that proTα and
478 proTα(100–109) optimize immunogenic peptide-pulsed
479 DC functionalities in vitro, possibly by TLR-4 triggering.
480 Ex vivo education of DCs by proTα or proTα(100–109)
481 results in their polarization to type-1 DCs, with increased
482 capacity to stimulate tumor peptide-specific T cell re-
483 sponses and to render cytotoxic T cells polyfunctional. If
484 this holds true also in vivo, then these molecules could be
485 promising components of DC-based anti-cancer vaccines.
486Methods
487Peptide synthesis
488ProTα(100–109), and the tumor antigen epitopes HER-2
489(9369), tyr(9369) (HLA-A2-restricted) [64], HER-2(15776)
490and tyr(15448) (HLA-DR4-restricted) [36,64] were syn-
491thesized by the Fmoc (9-fluorenylmethoxycarbonyl)/tBu
492chemistry utilizing a multiple peptide synthesizer Syro II
493(MultiSynTech, Witten, Germany). Crude peptides were
494purified by HPLC on a reverse phase C18 Nucleosil
495100-5C column (HPLC Technologies, UK) to a purity of
496>95%, using a linear gradient of 5.8% acetonitrile in 0.05%
497trifluoroacetic acid for 45 min. All peptides were charac-
498terized by matrix-assisted laser desorption ionization-time
499of flight mass spectrometry and results were in all cases in
500agreement with the calculated masses. Human recombin-
501ant proTα was purchased from Alexis Biochemicals, CA,
502USA and passed through an Endotoxin removal column
503(Pierce Biotechnology). Prior to their use, all peptides and
504proTα were tested for endotoxin levels using the LAL
505chromogenic Endotoxin Quantitation kit (Pierce Biotech-
506nology, IL, USA) according to the manufacturer’s instruc-
507tions. They were endotoxin-free.
508Cell lines and PBMC isolation
509Human T2 cells (HLA-A*0201) were cultured in RPMI
5101640, supplemented with 10% heat-inactivated fetal
511bovine serum (FBS), 2 mM L-glutamine, 10 mM Hepes,
5125 μg/mL Gentamycin, 10 U/mL Penicillin and 10 U/mL
513Streptomycin (all from Lonza, Cologne, Germany), at
51437°C, in a humidified 5% CO2 incubator.
515Buffy coats were collected from HLA-A2+ and DR4+
516healthy blood donors. Prior to blood draw, individuals
517gave their informed consent according to the regulations
518approved by the 2nd Peripheral Blood Transfusion Unit
519and Haemophilia Centre, ‘Laikon’ General Hospital Insti-
520tutional Review Board, Athens, Greece. PBMCs were iso-
521lated by centrifugation over Ficoll-Histopaque (Lonza)
522density gradient, resuspended in X-VIVO 15 (Lonza) or
523cryopreserved in FBS-10% DMSO (Sigma-Aldrich Chem-
524ical Co., St Louis, MO, USA) for later use.
525DC maturation and T cell stimulation
526Highly enriched monocytes (>80% CD14+) were obtained
527from PBMCs by plastic adherence for 2 h at 37°C [65].
528Non-adherent cells were removed and cryopreserved.
529Monocytes were cultured for 5 days in X-VIVO 15
530supplemented with 800 IU/mL recombinant human
531granulocyte macrophage colony-stimulating factor (GM-
532CSF) and 500 IU/mL recombinant human IL-4 (both from
533R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany).
534On day 5, iDCs were treated with LPS (0.5 μg/mL;
535Sigma-Aldrich), TNF-α (10 ng/mL; R&D Systems),
536proTα (160 ng/mL) or proΤα(100–109) (25 ng/mL) for
5371–48 h, concentrations already reported to induce DC
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538 maturation [23]. Mature DCs were recovered at various
539 time points for phenotypic and TLR-4 analysis by flow
540 cytometry and immunoblotting, or were used to stimu-
541 late autologous T cells. Supernatants from 48 h ma-
542 tured DCs were also collected and the concentrations
543 of TNF-α, IL-10 and IL-12 were quantified using com-
544 mercially available ELISA kits (all from Life Technologies
545 Corporation, Carlsbad, USA), according to manufacturer’s
546 instructions. For TLR-4 neutralization experiments,
547 iDCs were pre-incubated in the presence of anti-TLR-4
548 (a-TLR-4) neutralizing monoclonal antibody (mAb;
549 clone W7C11) or an irrelevant mouse IgG1 mAb (both
550 from InvivoGen, San Diego, USA) at a final concentra-
551 tion of 10 μg/mL for 1 h and further stimulated with
552 LPS, proTα or proTα(100–109) for 48 h. TNF-α, IL-10
553 and IL-12 were determined in culture supernatants.
554 For T cell stimulation, 48 h matured DCs (1×106/mL)
555 were pulsed with 50 μg/mL HER-2(9369) and HER-2
556 (15776) for 6 h at 37°C, in a humidified 5% CO2 incuba-
557 tor in X-VIVO 15. DCs were washed twice, resuspended
558 in X-VIVO 15 and added to autologous lymphocytes
559 (non-adherent fraction) at a DC:lymphocyte ratio of
560 1:10. T cells were stimulated thrice at weekly intervals
561 and on days 3 and 5 after each stimulation, 40 IU/mL
562 IL-2 (Proleukin; Novartis Pharmaceuticals Ltd, UK) were
563 added to the cultures. At the third stimulation, Golgi-
564 Plug (1 μL/mL; Becton-Dickinson (BD) Biosciences,
565 Erembodegem, Belgium) was added in the cultures, and
566 12 h later, T cells were harvested and analyzed for cyto-
567 kine production by flow cytometry.
568 Flow cytometry analysis
569 For DC phenotype analysis, iDCs and mature DCs were
570 stained for the surface molecules HLA-DR, CD80,
571 CD83, CD86, CD11b, CD40 and CD14. Triple staining
572 was performed using appropriate combinations of FITC-,
573 PE- or PE-Cy5-labelled mouse anti-human IgG1 and IgG2
574 mAbs (BD Biosciences) at saturating concentrations for
575 30 min on ice. DCs were also stained with irrelevant anti-
576 human IgG1 and IgG2 mAbs (BD Biosciences), as isotype
577 controls. Samples were measured using a FACSCalibur
578 flow cytometer (BD Biosciences) and data were analyzed
579 using CellQuest software. MFI was evaluated for each
580 marker.
581 For TLR-4 expression, iDCs and DCs matured with
582 LPS, proTα or proTα(100–109) for 15 min, 30 min, 1 h,
583 18 h and 36 h were harvested and treated with human im-
584 munoglobulin (GAMUNEX; Bayer, Leverkusen, Germany)
585 and ethidium monoazide (EMA; Invitrogen, Karlsruhe,
586 Germany) to block Fc receptors and label nonviable cells,
587 respectively. DCs were then stained with TLR-4/Brilliant
588 Violet 421, CD11c/PE-Cy7 (both from BioLegend, San
589 Diego, CA) and Lineage 1 cocktail/FITC (BD Biosciences)
590 mAbs and measured immediately using LSR II or
591FACSCanto II and FACSDiva software (BD Biosciences).
592Data were analyzed using FlowJo software (TreeStar,
593Ashland, OR). Duplicates were excluded using the
594forward-scatter area versus forward-scatter height plot,
595TLR-4+ cells were gated within viable DCs (EMA-
596negative (−), CD11c + and Lineage 1-) and their MFI was
597determined. For TLR-4 neutralization experiments, a-
598TLR-4-treated iDCs were stimulated as above and stained
599with CD14/FITC (BioLegend) and TLR-4/Brilliant Violet
600421 or PE (BioLegend) mAbs at saturating concentrations
601for 30 min on ice. DCs were also stained with irrelevant
602anti-human IgG2 mAbs (BD Biosciences), as isotype con-
603trols. Samples were measured using a FACSCanto II and
604data were analyzed using FACSDiva software.
605For cytokine production analysis, T cells were harvested
606and treated with GAMUNEX and EMA. They were
607then stained with the following mAbs: CD3/eFluor 605,
608IL-10/PE, and IL-17/PerCP-Cy5.5 (eBioscience, San
609Diego, CA); CD-4/PerCP, CD-8/APC-H7, IL-4/APC, IFN-
610γ/PE-Cy7 and CD107a/FITC (BD Biosciences); IL-2/
611Alexa700 and TNF-α/Brilliant Violet 421 (BioLegend).
612Samples were analysed immediately using an LSR II and
613FACSDiva software and data were processed using FlowJo
614software. Duplicates were excluded using the forward-
615scatter area versus forward-scatter height plot, and CD4+
616and CD8+ cells were gated within viable CD3+ lympho-
617cytes and analyzed separately for cytokine production.
618The percentage of cells producing each cytokine on gated
619T cells was determined.
620Cytotoxicity assay
621The cytotoxic activity of thrice stimulated T cells was de-
622termined by standard 51Cr- release assay. T2 cells were in-
623cubated for 2 h at 37°C with 10 μg/mL HER-2(9369) or tyr
624(9369), washed and labeled with sodium chromate, as pre-
625viously described [21]. Non-loaded T2 were similarly
626labeled for controls. Effectors (1×106/mL in X-VIVO 15;
627100 μL/well) were seeded in 96-well U-bottom plates
628(Greiner Bio-one, Kirchheim, Germany) and T2 targets
629were added (5×104/mL; 100 μL/well), at an effector:target
630(E:T) ratio of 10:1. Where indicated, mAb to MHC class I
631molecules (W6/32, kindly donated by Prof. S. Stevanovic,
632University of Tübingen) was added to the cultures at a
633final concentration of 5 μg/mL for the entire incubation
634period [66]. After 18 h of coincubation at 37°C, 5% CO2,
635100 μL of supernatant were removed from each well and
636isotope (counts per minute (cpm)) was counted in a γ-
637counter (1275 Mini-gamma LKB Wallac, Turku, Finland).
638To determine maximal and spontaneous isotope re-
639lease, targets were incubated with 3 N HCl and in plain
640medium, respectively. All cultures were set in triplicate.
641Percentage of specific cytotoxicity was calculated according
642to the formula: [(cpm experimental-cpm spontaneous)/
643(cpm maximal-cpm spontaneous)] ×100.
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644 Proliferation assay
645 Stimulated T cells were seeded in 96-well U-bottom
646 plates (1 × 106/mL; 100 μL). Autologous matured DCs
647 pulsed with 50 μg/mL HER-2(15776) or tyr(15448) for 6
648 h, were added (1 × 105/mL; 100 μL/well) and cocultured
649 for 5 days. T cells incubated with unpulsed matured DCs
650 or in the presence of IL-2 (500 IU/mL) were used as
651 controls. Where indicated, mAb to MHC class II mole-
652 cules (L243, kindly donated by Prof. S. Stevanovic) was
653 added to the cultures at a concentration of 5 μg/mL for
654 the entire culture period [66]. For the last 18 h of cul-
655 ture, 1 μCi 3H-thymidine (Amersham Pharmacia Bio-
656 tech, Amersham, Bucks, UK) was added per well and
657 cells were harvested in a semi-automatic cell harvester
658 (Skatron Inc., Tranby, Norway). The amount of incorpo-
659 rated radioactivity, proportional to DNA synthesis, was
660 measured in a liquid scintillation counter (Wallac,
661 Turku, Finland) and expressed as cpm. The S.I. of each
662 experimental group was calculated using the formula:
663 (average cpm of sample in the presence of peptide-
664 pulsed DCs)/(average cpm of sample in the presence of
665 unpulsed DCs).
666 Immunoblotting
667 Total cell extracts from 4–5×105 iDCs and DCs matured
668 with LPS, proTα or proTα(100–109) were extracted as de-
669 scribed [67]. Briefly, cells were lysed in NP-40 lysis buffer
670 (1% NP-40, 150 mM NaCl, 50 mM Tris pH 8.0)
671 containing protease inhibitors (Protease Inhibitor Cocktail,
672 Sigma-Aldrich) and lysates were cleared by centrifugation
673 for 10 min at 19,000 g (4°C). The protein content of ex-
674 tracts was determined by the Bradford assay, samples
675 were mixed with reducing Laemmli buffer and equal
676 protein amounts (15–25 μg) were separated by sodium
677 dodecyl sulfate–polyacrylamide gel electrophoresis using
678 12% (w/v) polyacrylamide gels. Separated proteins were
679 blotted on nitrocellulose membranes and probed with pri-
680 mary antibodies (goat anti-human ΤRIF/Novus Biologi-
681 cals, Ltd, Cambridge, UK; rabbit anti-human MyD88 and
682 rabbit anti-human TIRAP/eBioscience; rabbit anti-human
683 GAPDH/Santa Cruz Biotechnology Inc, Santa Cruz, CA,
684 USA) and horseradish peroxidase (HRP)-conjugated sec-
685 ondary antibodies (anti-rabbit-IgG and anti-goat-IgG/
686 Santa Cruz Biotechnology). Immunoblots were developed
687 using an enhanced chemiluminescence reagent kit (Santa
688 Cruz Biotechnology) and quantified by scanning densi-
689 tometry (Gel Analyzer v.1.0, Biosure, Athens, Greece).
690 Statistical analysis
691 Data were analyzed by the Student’s t-test and statis-
692 tical significance was presumed at significance level of
693 5% (p < 0.05).
694Additional files
695
697Additional file 1: Table S1. Range of % cytokine positive CD4+ and
698CD8+ T cells. (A) Intracellular production of IFN-γ, TNF-α, IL-2, IL-4, IL-10
699and IL-17 in, and expression of CD107 on CD4+ and CD8+ T cells
700stimulated with DCs matured with TNF-α, proTα or proTα(100–109), in
701the absence (−) or presence (+) of the HER-2/neu peptides. IL-5+ and
702IL-13+ CD8+ T cells are additionally shown. Numbers indicate
703percentages of positive cells. Shown is the range detected from 3–5
704different donors tested. (B) Ratios of IFN-γ/IL-5 and IFN-γ/IL-13 in CD8+ T cells.
705Shown is the range from 3 different donors tested.
706Additional file 2: Figure S1. Kinetics of CD14 and TLR-4 surface
707expression on monocytes, macrophages and iDCs/DCs upon stimulation
708with LPS, proTα or proTα(100–109). Monocytes, macrophages and iDCs
709(0 h) were stimulated with LPS (A), proTα (B), or proTα(100–109) (C) for
71015 min, 30 min, 1 h and 18 h and assessed for the surface expression of
711CD14 and TLR-4 using flow cytometry. MFI values in the presence of
712neutralizing anti-TLR-4 Ab (+ a-TLR-4) are shown below each histogram.
713Histograms are from one representative donor of 3 tested. Using the loss
714of cell surface expression as a readout for TLR-4 and CD14 endocytosis
715from 0–36 h [31], data from all three donors are shown as mean values ± SDs
716for TLR-4 (D, E, F) and CD14 (G, H, I).
717Additional file 3: Figure S2. CD14, TLR-4 and CD206 expression on
718monocytes, monocyte-derived macrophages and monocyte-derived iDCs.
719Macrophages were generated from human monocytes upon incubation
720with 100 ng/mL GM-CSF for 5 days. Human monocytes were isolated
721and iDCs were generated as described in Methods. Monocytes,
722macrophages and iDCs were assessed for the surface expression of CD14,
723TLR-4 and CD206 (as a specific marker for macrophages and DCs), using
724flow cytometry. Histograms are from one representative donor of 3
725tested and numbers indicate MFIs.
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